Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment

Acta Haematologica

Volumn 125, Issue 3, 2011, Pages 121-124

  Kim, Min Gang ^a   Park, So Young ^a   Kim, Eun Ji ^a   Kim, Yong Min ^a   Kim, Ho Young ^a   Lee, Young Kyung ^a   Zang, Dae Young ^a   Kim, Hyo Jung ^a,b  

^a Hallym University Medical Center   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Central nervous system lymphoma; Hepatitis B virus; Intrathecal rituximab; Non Hodgkin's lymphoma; Reactivation

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; RITUXIMAB;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL GANGLION; BILIRUBIN BLOOD LEVEL; BRAIN BIOPSY; BRAIN HEMORRHAGE; BRAIN RADIATION; CANCER RELAPSE; CASE REPORT; CEREBROSPINAL FLUID; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LIVER FUNCTION TEST; MALAISE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; STEREOTACTIC BIOPSY; THALAMUS; VIRUS REACTIVATION; WHITE MATTER;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INJECTIONS, SPINAL; VIRUS ACTIVATION;

EID: 78649777371     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321792     Document Type: Article

References (17)

1. Ferreri AJ, Reni M, Villa E: Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000; 11: 927-937.
2. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Jouvet A, Barbui T, Cavalli F, Blay JY: A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-1520. (Pubitemid 34552959)
3. Reni M, Ferreri AJ: Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 2001; 80(suppl 3):B113-B117.
4. Hong SJ, Kim JS, Chang JH, Kim KM, Kim SJ, Lee HW, Cheong JW, Lee ST, Min YH: A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J 2009; 50: 280-283.
5. Antonini G, Cox MC, Montefusco E, Ferrari A, Conte E, Morino S, Latino P, Trasimeni G, Monarca B: Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 2007; 81: 197-199. (Pubitemid 44963979)
6. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M: Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25: 1350-1356. (Pubitemid 46706881)
7. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002; 59: 213-216. (Pubitemid 35021571)
8. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753-754. (Pubitemid 38828486)
9. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N: Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629. (Pubitemid 38196051)
10. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N, Onji M: Anti- HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721-724. (Pubitemid 44027603)
11. Kim EB, Kim DS, Park SJ, Park Y, Rho KH, Kim SJ: Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat 2008; 40: 36-38.
12. Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P: Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-1056. (Pubitemid 44564520)
13. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930. (Pubitemid 37022596)
14. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
15. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N: Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608. (Pubitemid 40723731)
16. Lubel JS, Testro AG, Angus PW: Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37: 705- 712. (Pubitemid 47481164)
17. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G: Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528. (Pubitemid 351665421)